Mini-Review Article

靶向治疗肺癌的疫苗:进展与发展

卷 25, 期 8, 2024

发表于: 06 May, 2024

页: [526 - 529] 页: 4

弟呕挨: 10.2174/0113894501306103240426131249

价格: $65

Open Access Journals Promotions 2
摘要

考虑到肺癌是全球主要的肇事者,必须研究新的治疗方法。由于肺癌的广谱性,包括化疗、放疗和手术在内的传统治疗方法并不总是有效,而且可能产生不良后果。本研究的总体目标是加强针对肺癌治疗的个性化疫苗的开发。疫苗的作用是通过利用肺癌细胞表达的特异性抗原,引发强大的、有针对性的免疫反应防御。本文综述了与肿瘤细胞相关的关键抗原,并对肺癌的遗传和免疫学情况进行了认识。这种疫苗含有这些抗原,以启动免疫系统,引导其识别和攻击癌细胞。在这篇综述中,我们讨论了靶向疫苗策略可能带来的益处,包括减少脱靶效应和改善患者的健康结果。这些研究强调了以一种新方式治疗肺癌的量身定制疫苗的前景。分子谱分析和免疫学见解的整合为个性化疫苗的设计和实施提供了基本原理。尽管存在挑战,但改善治疗结果和减少副作用的前景使靶向疫苗治疗成为推进肺癌治疗的一个令人信服的途径。

关键词: 肺癌,疫苗,免疫治疗,靶向治疗,癌症,病人护理。

图形摘要
[1]
Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat 2020; 53: 100715.
[http://dx.doi.org/10.1016/j.drup.2020.100715] [PMID: 32679188]
[2]
Abbas S, Selamoglu Z, Sevindik M, et al. Enhanced heterologous immuno-boost (EHIB) covid-19 vaccines: A novel concept. Eurasian J Med Biol Sci 2023; 3(2): 67-79.
[3]
Nabavi Sf, Habtemariam S, Daglia M, Sureda A, Sobarzo E. Melatonin and respiratory diseases a review. Curr Top Med Chem 2017; 17(24): 1-22.
[4]
Selamoglu M. Importance of the cold chain logistics in the marketing process of aquatic products: An updated study. J Surv Fish Sci 2021; 25-9.
[http://dx.doi.org/10.18331/SFS2021.8.1.2]
[5]
Malvankar C, Kumar D. AXL kinase inhibitors-A prospective model for medicinal chemistry strategies in anticancer drug discovery. Biochim Biophys Acta Rev Cancer 2022; 1877(5): 188786.
[6]
Giaccone G, Bazhenova LA, Nemunaitis J, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer 2015; 51(16): 2321-9.
[http://dx.doi.org/10.1016/j.ejca.2015.07.035] [PMID: 26283035]
[7]
Durgeau A, Virk Y, Gros G, et al. Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nat Commun 2018; 9(1): 5097.
[http://dx.doi.org/10.1038/s41467-018-07603-1] [PMID: 30504837]
[8]
Zara R, Rasul A, Sultana T, Jabeen F, Selamoglu Z. Identification of Macrolepiota procera extract as a novel G6PD inhibitor for the treatment of lung cancer. Saudi J Biol Sci 2022; 29(5): 3372-9.
[http://dx.doi.org/10.1016/j.sjbs.2022.02.018] [PMID: 35865797]
[9]
Selamoglu-Talas Z, Ozdemir I, Ciftci O, Cakir O. Propolis attenuates oxidative injury in brain and lung of nitric oxide synthase inhibited rats. J Pharm Care 2013; 45-50.
[10]
Talas ZS, Ozdemir I, Yilmaz I, Gok Y. Antioxidative effects of novel synthetic organoselenium compound in rat lung and kidney. Ecotoxicol Environ Saf 2009; 72(3): 916-21.
[http://dx.doi.org/10.1016/j.ecoenv.2007.11.012] [PMID: 18222543]
[11]
García-Pardo M, Gorria T, Malenica I, Corgnac S, Teixidó C, Mezquita L. Vaccine therapy in non-small cell lung cancer. Vaccines 2022; 10(5): 740.
[http://dx.doi.org/10.3390/vaccines10050740] [PMID: 35632496]
[12]
Rodriguez PC, Popa X, Martínez O, et al. A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non–small cell lung cancer patients. Clin Cancer Res 2016; 22(15): 3782-90.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0855] [PMID: 26927662]
[13]
Hirschowitz EA, Mullins A, Prajapati D, et al. Pilot study of 1650-G: A simplified cellular vaccine for lung cancer. J Thorac Oncol 2011; 6(1): 169-73.
[http://dx.doi.org/10.1097/JTO.0b013e3181fb5c22] [PMID: 21150468]
[14]
Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomized, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 59-68.
[http://dx.doi.org/10.1016/S1470-2045(13)70510-2] [PMID: 24331154]
[15]
Pujol JL, De Pas T, Rittmeyer A, et al. Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non–small cell lung cancer: A phase I dose escalation study. J Thorac Oncol 2016; 11(12): 2208-17.
[http://dx.doi.org/10.1016/j.jtho.2016.08.120] [PMID: 27544054]
[16]
Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 2008; 3(7): 735-44.
[http://dx.doi.org/10.1097/JTO.0b013e31817c6b4f] [PMID: 18594319]
[17]
Jou J, Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EEW. The changing landscape of therapeutic cancer vaccines—novel platforms and neoantigen identification. Clin Cancer Res 2021; 27(3): 689-703.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-0245] [PMID: 33122346]
[18]
Alfonso S, Valdés-Zayas A, Santiesteban ER, et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 2014; 20(14): 3660-71.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-1674] [PMID: 24788102]
[19]
Somaiah N, Block MS, Kim JW, et al. First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1. Clin Cancer Res 2019; 25(19): 5808-17.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-1025] [PMID: 31227504]
[20]
Donninger H, Li C, Eaton JW, Yaddanapudi K. Cancer vaccines: Promising therapeutics or an unattainable dream. Vaccines 2021; 9(6): 668.
[http://dx.doi.org/10.3390/vaccines9060668] [PMID: 34207062]
[21]
Addeo A, Friedlaender A, Giovannetti E, et al. A new generation of vaccines in the age of immunotherapy. Curr Oncol Rep 2021; 23(12): 137.
[http://dx.doi.org/10.1007/s11912-021-01130-x] [PMID: 34735649]
[22]
Gridelli C, Ciuleanu T, Domine M, et al. Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: Final results of a randomised phase 2 clinical trial. Br J Cancer 2020; 122(10): 1461-6.
[http://dx.doi.org/10.1038/s41416-020-0785-y] [PMID: 32210365]
[23]
Voena C, Menotti M, Mastini C, et al. Efficacy of a cancer vaccine against ALK-rearranged lung tumors. Cancer Immunol Res 2015; 3(12): 1333-43.
[http://dx.doi.org/10.1158/2326-6066.CIR-15-0089] [PMID: 26419961]
[24]
First vaccine for treating ALK-positive lung cancer LUNGevity found. Available from: https://www.lungevity.org/blogs/developing-first-vaccine-for-treating-alk-positive-lung-cancer (accessed on 17 March 2022).
[25]
Sankar K, Nagrath S, Ramnath N. Immunotherapy for ALK-rearranged non-small cell lung cancer: Challenges inform promising approaches. Cancers 2021; 13(6): 1476.
[http://dx.doi.org/10.3390/cancers13061476] [PMID: 33806977]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy